A GLP-1 Benefit Strategy That Isn't a Blank Check: The Employer Guide

Employees are asking for GLP-1 coverage, uncapped pharmacy coverage is fiscally untenable, and cash stipends create compliance exposure. A capped Specialty HRA gives employees a defined, tax-free GLP-1 allowance while setting your maximum exposure in advance. Employees fill the allowance through manufacturer-direct cash-pay pricing.

The Demand Problem

GLP-1 medications have become the single most-requested benefit in many workforces, and the request isn't going away. For employers, the pressure comes from every direction at once: employees asking directly, recruiting conversations where coverage is a differentiator, and renewal meetings where GLP-1 utilization is driving the trend line.

The math is what makes this hard. List prices run to five figures per patient per year, demand is broad rather than confined to a small clinical population, and duration of therapy is long. A benefit that costs $10,000+ per participant per year, that a large fraction of the workforce wants, behaves like a second health plan.

Why the Obvious Answers Fail

Uncapped pharmacy coverage. Adding GLP-1s to the formulary without limits means your cost is (number of employees who qualify) × (net price) × (as long as they stay on therapy). You control none of those variables. Employers who've done it have watched the line item grow until it forced mid-year clawbacks: new prior-authorization hurdles, BMI thresholds, or outright removal. Giving a benefit and then visibly taking it away is worse for trust than never offering it.

Doing nothing. Defensible on cost, but it concedes the recruiting and retention ground to employers who found a structure that works. It also pushes employees toward gray-market compounding pharmacies, which is its own problem.

A cash stipend. The tempting middle path: "we'll give you $200/month toward your GLP-1." Two problems. First, it's taxable. The both-sides tax toll means a meaningful share of every dollar evaporates. Second, and more seriously, an employer paying for employees' medical care outside a proper plan structure can be treated as sponsoring a group health plan, pulling in ERISA, COBRA, and ACA obligations a stipend was never designed to satisfy. A "simple" stipend for prescription drugs is arguably the least simple option on the table. Worth confirming with benefits counsel before going anywhere near it.

The Capped Specialty HRA Approach

A Health Reimbursement Arrangement is employer-funded and tax-free to the employee. The employer sets its scope and cap. A Specialty HRA narrows that scope to a defined category: in this case, GLP-1 medications, with a monthly or annual cap you choose.

	Uncapped pharmacy coverage	Cash stipend	Capped Specialty HRA
Cost exposure	Open-ended	Capped	Capped, employer-defined
Tax treatment	Pre-tax	Taxable both sides	Tax-free to employee, no FICA
Compliance posture	Inside the health plan	Group-health-plan exposure without the structure	Proper plan documents, built for purpose
Budget predictability	None	High	High, cap × enrollment is your ceiling

Because the HRA is a real plan with plan documents and adjudication, it avoids the group-health-plan exposure a bare stipend creates. The money is tax-free precisely because it runs through the right structure.

Cash-Pay Pricing Makes the Cap Go Further

The other half of the strategy is where employees spend the allowance. Manufacturer-direct cash-pay programs now sell GLP-1s at prices far below list, often below what many plans pay net of rebates. An employee combining a capped HRA allowance with manufacturer-direct pricing can cover most or all of their monthly cost, without your plan carrying the drug at all.

This is what makes a defined allowance useful rather than symbolic: the cap is sized against a real, published cash price, not a five-figure list price.

Preserving HSA Eligibility (and the PPO Case)

One detail that trips up well-intentioned designs: employees must be HSA-eligible to receive HSA contributions or contribute themselves. They must be on an HDHP with no disqualifying coverage. A carelessly structured HRA that pays medical expenses before the HDHP deductible is disqualifying coverage, and it can quietly cost your HDHP population their $4,400/$8,750 contribution capacity and its triple tax advantage.

A properly designed GLP-1 Specialty HRA is built to preserve HSA eligibility alongside HDHPs. For employees on PPO plans, where HSA eligibility isn't in play, the HRA can instead use HRA-pays-first ordering. The allowance applies before the employee's own money does. The ordering changes with plan type. The clinical leg needs the same care: employer-arranged telehealth is its own HSA-eligibility question under the rules, separate from the HRA, and the program is designed so that leg sits within the telehealth safe harbor. The administrator should handle these details, with benefits counsel confirming the design either way.

How Hammock Helps

Hammock's GLP-1 Specialty HRA is the capped structure described above, delivered as a managed product: you set the allowance, Hammock handles plan documents, claims adjudication, and compliance. Hammock also runs the clinical side of the program through its own telehealth network. Licensed clinicians evaluate employees, prescribe GLP-1 medications when clinically appropriate, and track adherence. Employees fill their prescriptions through manufacturer-direct cash-pay programs and the HRA reimburses tax-free up to the cap. There's no PBM in the middle.

The design preserves HSA eligibility for HDHP populations and pairs with PPOs using HRA-pays-first ordering, so it drops into your existing plan lineup rather than fighting it. Like the rest of Hammock, including full HSA/FSA administration and LMN-based wellness coverage, it comes with white-glove support and launches quickly.

FAQ

Why not just add GLP-1s to our pharmacy benefit?

Because the exposure is uncapped: broad demand, high monthly cost, and long therapy duration mean the line item compounds until it forces restrictions or removal. A capped allowance gives employees real help while keeping your maximum spend defined.

Is a GLP-1 cash stipend a compliance problem?

It can be. An employer paying for employees' medical care outside a proper plan structure risks being treated as sponsoring a group health plan, with ERISA, COBRA, and ACA obligations attached. The stipend is taxable on both sides regardless. This isn't tax or legal advice; confirm your specific design with benefits counsel.

Will a GLP-1 HRA break HSA eligibility for employees on our HDHP?

A badly designed one can. Hammock's Specialty HRA is specifically structured to preserve HSA eligibility alongside HDHPs; for PPO employees, it uses HRA-pays-first ordering instead.

How do employees afford GLP-1s on a capped allowance?

Manufacturer-direct cash-pay programs price GLP-1s well below list. A cap sized against cash-pay pricing can cover most or all of an employee's monthly cost, which an allowance sized against list price never could.

What does the employer have to administer?

Very little. Hammock handles plan documents, adjudication, and compliance. You choose the cap and eligibility; Hammock's own telehealth network handles the clinical side, including prescribing, and there's no PBM integration.

The Bottom Line

GLP-1 demand is real and durable. Uncapped coverage leaves employer cost open-ended, doing nothing leaves employees without coverage, and cash stipends carry tax and compliance risks. A capped Specialty HRA plus manufacturer-direct cash-pay pricing gives employees meaningful, tax-free help with your exposure fixed in advance, structured so it doesn't blow up HSA eligibility or your compliance posture.

Want to see what a capped GLP-1 benefit would cost at your headcount? Talk to our team.